CHOC Press Room :: Related News
New Innovation in the AYA Cancer Movement: The Future Is Here
January 15, 2014
SAYAO held their first annual conference at the University of California, Irvine (UC Irvine), in partnership with the Hyundai Cancer Institute at the Children's Hospital of Orange County (CHOC Children's).
Advances in the Young Adult Cancer Movement: Why Sayao Is a Big Deal
December 16, 2013
SAYAO was envisioned and developed under the leadership of Dr. Leonard Sender, a pediatric and adult Hematologist/Oncologist.
The Future of the AYA Cancer Movement: A Chat With Dr. Leonard Sender
December 03, 2013
Dr. Sender is regarded as one of the leading advocacy pioneers of the adolescent and young adult (AYA) oncology movement
Dr. Leonard Sender to Appear on American Health Journal on Friday, July 26 at 5:30 p.m.
July 25, 2013
CHOC Children’s adopts new genome sequencing service
August 15, 2012
The service is part of a study to improve pediatric cancer treatment.
New Study to Explore Efficacy of Narcotics in Managing Kids’ Pain
August 15, 2012
Hyundai Cancer Institute at CHOC Children’s is First to Utilize Illumina’s RapidTrack Whole Genome Sequencing Service For Cancer Study
August 13, 2012
As part of a pilot study designed to advance personalized treatment for children and teens battling recurrent cancer, the Hyundai Cancer Institute at CHOC Children’s is the first organization to utilize Illumina’s RapidTrack Whole Genome Sequencing (RapidTrack WGS) service for cancer samples.
CHOC Children’s Research Project Awarded $5.5 Million Grant from the California Institute for Regenerative Medicine
May 29, 2012
A CHOC Children’s research project, under the direction of Philip H. Schwartz, Ph.D., senior scientist at the CHOC Children’s Research Institute and managing director of the facility’s National Human Neural Stem Cell Resource, has been awarded a $5.5 million grant from the California Institute for Regenerative Medicine (CIRM). The grant will be used to develop a stem cell- based therapy for the treatment of mucopolysaccharidosis (MPS I).
Work of Diane Nugent, M.D., Medical Director, CHOC Children's Hematology, Lays Foundation for Recent FDA Approval of Factor XIII Concentrate to Treat Rare and Potentially Fatal Bleeding Disorder
April 12, 2011
In 1998, Dr. Nugent, CHOC Research Administration and Dr. Nugent's clinical research team at CHOC Children's assumed oversight of a compassionate use drug study for FXIII- deficient patients. Since that time, they have supplied treatment to more than 60 patients, and collected safety and efficacy data that helped create the foundation of evidence for the successful FDA approval.
CHOC Children's Scientist Honored with Trailblazer Award From Autism Speaks
January 06, 2011
Philip H. Schwartz, Ph.D., senior scientist at the CHOC Children’s Research Institute and managing director of the facility’s National Human Neural Stem Cell Resource, was recently awarded a “Bob and Suzanne Wright Trailblazer Award” from Autism Speaks, the world’s largest autism science and advocacy organization.
CHOC Children's Receives $3 Million NIH Award To Use Stem Cells To Sudy The Impact Of Autism On The Living Brain
August 11, 2009
CHOC Children's announced today that its Research Institute has received a five-year, $3 million National Institutes of Health (NIH) Research Grant to generate, investigate, and store neural stem cells derived from skin cells (fibroblasts) donated by children with autism. The research program is designed to provide an important new tool for studying the impact of autism on the developing brain -- in a completely harmless and non-invasive way -- while assembling the first repository of neural cells from living patients as a resource for the entire autism research community
CHOC Children's Joins Excell Pivotal Study For Leukemia And Lymphoma Patients As Only Pediatric Site On West Coast
February 11, 2009
CHOC Children's is the only pediatric site for the ExCell study on the West Coast. The pivotal registration study is testing the safety and efficacy of StemEx, a potential alternative transplantation option for adolescents and adults with leukemia, lymphoma and other high-risk hematological malignancies, who are unable to find an adequately matched, bone marrow donor.
CHOC and UCI to Create World-Class Center for Children's Health
November 21, 2008
Children's Hospital of Orange County, UC Irvine Healthcare and UC Irvine School of Medicine will form a strategic affiliation to better serve children and families.
Children's Hospital of Orange County Receives Federal Award to Derive Embryonic Stem Cells from Adult Cells
June 17, 2008
Children's Hospital of Orange County (CHOC) just received a one-of-a-kind funding award from the National Institutes of Health (NIH). This award establishes CHOC as having the first federally-funded training grant to receive additional federal funding to incorporate new embryonic stem cell derivation technology as part of its training curriculum. This curriculum is a critical adjunct to the NIH's recent stem cell initiative that will fund new research grants that propose to use this new technology.
CHOC Scientist Investigates Stem Cell Biology in Degenerative Diseases
March 14, 2007
A researcher from Children’s Hospital of Orange County (CHOC), Phillip Schwartz, Ph.D., is among an international collaborative group of scientists who have shown, for the first time, that human neural stem cells, of either adult or embryonic origin, can treat degenerative diseases safely and effectively, and do so by invoking multiple mechanisms.
Type 1 Diabetes TrialNet Selects CHOC as "Major Affiliate"
February 08, 2007
CHOC Research Institute placed at the international forefront of diabetes research.
CHOC Receives Phase 1 Clinical Trial Designation
January 01, 2007
CHOC Selected To Conduct National Children's Study
October 03, 2005
CHOC participates in landmark study of pediatric health.